Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Institut de Cancérologie de Lorraine
Institut de Cancérologie de Lorraine
Centre Oscar Lambret
Henry Ford Health System
Fudan University
University Hospital, Lille
Criterium, Inc.
Institut Bergonié
Medical College of Wisconsin
Qilu Hospital of Shandong University
Fudan University
The Cleveland Clinic
Xijing Hospital
Yale University
GERCOR - Multidisciplinary Oncology Cooperative Group
Nizhny Novgorod Regional Clinical Oncology Center
Fudan University
SOLTI Breast Cancer Research Group
City of Hope Medical Center
Institut du Cancer de Montpellier - Val d'Aurelle
Gritstone bio, Inc.
Mercy Medical Center
Case Comprehensive Cancer Center
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Case Comprehensive Cancer Center
Icahn School of Medicine at Mount Sinai
University of Nebraska
University of Nebraska
University of Nebraska
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Suzhou Municipal Hospital
The First Affiliated Hospital of Zhengzhou University
Yonsei University
Mayo Clinic
Wake Forest University Health Sciences
ChineseAMS
Professor Fernando Figueira Integral Medicine Institute
European Organisation for Research and Treatment of Cancer - EORTC
University of Texas Southwestern Medical Center
Case Comprehensive Cancer Center
UNICANCER
Royal Marsden NHS Foundation Trust
Case Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Peking University
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mayo Clinic